Kornimate/medical-research-clean huggingface dataset:
role of echocardiography in pulmonary embolism

Conditions: Pulmonary Embolism

Summary: 1. to analyze the diagnostic and prognostic value of echocardiographic parameters. 2. prediction of ape-related 30-day mortality and adverse out comes. 3. the need for rescue thrombolysis in initially normotensive acute pulmonary embolism (ape) patients.

acute pulmonary embolism (ape) is the most serious clinical presentation of venous thromboembolism (vte). according to registries and hospital discharge databases of unselected patients with acute pulmonary embolism and venous thromboembolism , 30-day all-cause mortality rates are between 9% and 10%. according to the recent european society of cardiology (esc) guidelines on the diagnosis and treatment of acute pulmonary embolism patients, clinical classification of the severity of an episode of acute pulmonary embolism is based on the estimated 30-day acute pulmonary embolism - related mortality risk. patients with cardiogenic shock caused by acute pulmonary embolism comprise a high-risk group for early death, which is estimated at more than 15%. fortunately most acute pulmonary embolism patients are hemodynamically stable at admission but the early mortality risk is different in this population. risk stratification of non-high-risk acute pulmonary embolism patients is based on clinical presentation, cardiac laboratory biomarkers, and signs of right ventricular (rv) dysfunction on echocardiography or computed tomography. low-risk patients require a short hospital stay and can be early discharged home or even treated as outpatients. intermediate-risk subjects comprise a very heterogeneous group in which the early mortality ranges between 2% and 15%. more of these patients stabilize hemodynamically during anticoagulation, but in some of them clinical deterioration occurs and therefore they may require rescue thrombolysis or surgical or percutaneous embolectomy. echocardiography is a useful diagnostic tool to detected right ventricular (rv) dysfunction. it was reported that tricuspid annulus plane systolic excursion (tapse) can be used for risk stratification of normotensive ape patients. the tricuspid regurgitation peak gradient (trpg) is an echocardiographic sign of rv overload and it can also be used for risk stratification in acute pulmonary embolism .

Eligibility criteria:
inclusion criteria: 1. age \>18 and \<70 years. 2. patients with intermediate- risk pulmonary embolism will be 1. -hemodynamically stable at admission with systolic blood pressure * 90 mmhg and without signs of peripheral hypoperfusion. 2. - elevated cardiac biomarkers levels (particularly, a positive cardiac troponin test exclusion criteria: * 1- age \<18 years. 2- patients diagnosed with chronic thromboembolic hypertension. 3- patients with valvular heart diseases. 4- patients with lung cancer. 5- acute massive pulmonary embolism.
treatment of coronary de-novo stenosis by a sirolimus coated balloon or a paclitaxel coated balloon catheter

Conditions: Coronary Artery Disease

Summary: to examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon

to examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus a paclitaxel coated balloon. prospective, multicenter, randomized, single-blind, 70 patients. experimental intervention: predilatation of coronary de-novo stenosis followed by a sirolimus coated sequent®scb balloon (sirolimus 4.0 μg/mm²). control intervention: predilatation of coronary de-novo stenosis followed by a sequent®please or sequent®please neo balloon (paclitaxel 3.0 μg/mm²). follow-up per patient: 30 days telephone call; 6 months angiographic + 12 months. clinical follow up key inclusion criteria: \> 18 years of age, clinical evidence of stable or unstable angina or a positive functional study, patients with significant coronary de-novo stenosis (≥ 70% diameter stenosis or intermediate ≥ 50% to \ 30%). key exclusion criteria: acute myocardial infarction within the past 72 hours (stemi or nstemi), intolerance and / or allergy to sirolimus, intolerance or allergy to paclitaxel and/or the delivery matrix (main ingredient: iopromide), patients with an ejection fraction of \< 30 %, reference vessel diameter (rvd) \< 2.5 mm, contraindication for whichever necessary accompanying medication. primary efficacy endpoint: late lumen loss in-segment at 6 months. key secondary endpoints: procedural success: \< 30% final diameter stenosis, no flow-limiting dissection (type c or higher), timi iii flow, and the absence of in-hospital mace. mace: cardiac death, target vessel myocardial infarction, and clinically driven target lesion revascularization in-hospital at 6 and at 12 months individual clinical endpoints at 6 and at 12 months: cardiac death, target lesion myocardial infarction, clinically driven target lesion revascularization, (stenosis ≥ 50% at follow-up angiography)

Eligibility criteria:
inclusion criteria: * clinical evidence of stable or unstable angina or a positive functional study * patients with significant coronary de-novo stenosis (≥ 70% diameter stenosis or intermediate ≥ 50% to \<70% diameter stenosis with positive functional test or symptom of ischemia) * successful lesion preparation (no flow-limiting dissection or a residual stenosis \> 30%) exclusion criteria: * acute myocardial infarction within the past 72 hours (stemi or nstemi) * intolerance and / or allergy to sirolimus * intolerance or allergy to paclitaxel and/or the delivery matrix (main ingredient: iopromide) * patients with an ejection fraction of \< 30 % * reference vessel diameter (rvd) \< 2.5 mm * contraindication for whichever necessary accompanying medication
pre-approval access single patient request for talquetamab in relapsed or refractory multiple myeloma

Conditions: Relapsed or Refractory Multiple Myeloma

Summary: the purpose of this pre-approval access program is to provide talquetamab for the treatment of participants with relapsed or refractory multiple myeloma.


Eligibility criteria:
comparative in-vivo wetting characteristics of silicone hydrogel materials with selected lens care systems

Conditions: Myopia; Astigmatism; Refractive Error

Summary: the purpose of this study is to evaluate the lipid uptake, wetting characteristics, and visual performance of air optix® aqua and acuvue® oasys® with hydraclear® contact lenses when used in conjunction with two contact lens care systems.

this study will be divided into two phases. in the pre-investigational phase (phase 1), participants will wear purevision contact lenses for 30 days and use renu® multiplus® for contact lens care. eligible participants will continue into the investigational phase (phase 2) and be randomly assigned to wear air optix® aqua contact lenses or acuvue® oasys® with hydraclear® contact lenses for a total of two months. for contact lens care, participants will use opti-free® puremoist® mpds and biotrue® for 30 days each.

Eligibility criteria:
inclusion criteria: * read and understand the participant information sheet; * read, sign, and date the informed consent; * be a current silicone hydrogel contact lens wearer using the contact lenses under a frequent replacement (bi-weekly or monthly) daily wear modality; * be classified as symptomatic and a depositor at the end of the replacement period according to protocol-specified criteria; * agree to wear study contact lenses as directed for the duration of the study and maintain the appointment schedule; * best corrected visual acuity of 6/9 or better in each eye; * normal eyes with the exception of the need for visual correction; * other protocol-defined inclusion criteria may apply. exclusion criteria: * known sensitivity or intolerance to any of the contact lenses or contact lens care products to be used; * monocular vision (only one eye with functional vision or only one eye fitted with contact lenses); * use of systemic medication which might interfere with contact lens wear or produce dry eye side effects; * systemic disease which might interfere with contact lens wear or produce dry eye side effects; * systemic or ocular allergies which might interfere with contact lens wear; * ocular disease which might interfere with contact lens wear; * active ocular infection; * use of any concomitant topical ocular medications during the study period; * previous ocular surgery; * pregnant, planning to become pregnant, or lactating at the time of enrollment; * participation in an investigational drug or device study within 30 days of entering this study; * other protocol-defined exclusion criteria may apply.

Keywords: contact lenses contact lens solution myopia astigmatism
a study to determine the optimal tolerated regime and safety of pep005 topical gel

Conditions: Actinic Keratoses

Summary: the purpose of this study is to determine the optimal tolerated regime of pep005 for the treatment of actinic keratoses of the face or face and scalp.

actinic keratoses (ak) is a common skin condition characterized by rough, scaly patches or sores on the top layer of the skin which if left untreated can progress to skin cancer. current treatments can cause scarring and hypopigmentation, be inconvenient, or require long treatment duration. non-invasive alternative therapy for treatment of ak lesions is thus being researched.

Eligibility criteria:
1. male patients at least 18 years of age. 2. post-menopausal female patients i.e., no menses for at least 12 consecutive months, or without a uterus. 3. four to eight clinically typical, visible and discrete ak lesions within a contiguous 25 cm2 treatment area on the face or face and scalp. 5. ability to follow study instructions and likely to complete all study requirements. 6. written informed consent has been obtained. 7. agreement from the patient to allow photographs of the selected ak treatment area to be taken and used as part of the study data package.

Keywords: actinic keratoses (ak) pep005 topical dermatology
study of efficacy and safety of seroquel (quetiapine fumarate) as mono-therapy for acute schizophrenic

Conditions: Schizophrenia

Summary: the primary objective of the study is to evaluate the efficacy of quetiapine fumarate (seroquel) with daily dose 600mg-750mg used as mono-therapy in the treatment of acute schizophrenic patients by evaluation of the change from baseline in panss total score at day 56 using the last observation carried forward (locf) method.


Eligibility criteria:
inclusion criteria: * provision of written informed consent for study participation before initiation of any study related procedures, signed by the patient's legal guardian * female and/or male, aged between 18 and 60 years (inclusive) * is hospitalised in a psychiatric unit with an acute episode of schizophrenia defined by ccmd-3 criteria as one of the following: \[20.1\] paranoid schizophrenia, \[20.2\] hebephrenic schizophrenia, \[20.3\] catatonic schizophrenia, \[20.5\] undifferentiated schizophrenia exclusion criteria: * ccmd-3 diagnosis of mental retardation * psychosis judged to be the direct physiological effect of an abused medication or substance
effect of nigella sativa in atorvastatin treated hyperlipidaemia

Conditions: Hyperlipidemia

Summary: this study will be 8 weeks randomized, double-blind, placebo-controlled trail to assess the effect of nigella sativa in 84 hyperlipidaemic patients. participants will be assessed at baseline and after 8 weeks of intervention. subjects will be randomized to receive either nigella sativa 500 mg capsule daily or placebo capsule identical to nigella sativa twice daily for 8 weeks. evaluation of lipid profile, sgpt, s.creatinine will be before and after 8 weeks of intervention. nigella sativa related adverse events will be identified. study outcome will establish safety and efficacy of nigella sativa in atorvastatin treated hyperlipidaemic patients

hyperlipidemia is one of the most important risk factors to cause atherosclerosis that ultimately triggers cardiovascular complications like myocardial infarction, ischemic stroke, peripheral vascular disease etc. these are considered as the leading cause of mortality and morbidity worldwide. nigella sativa has both lipid lowering and anti-oxidant potentials. in this regard nigella sativa can be given with standard therapy to regulate blood lipids. aim of this study: this proposed study is therefore an effort to find out the safety and efficacy of nigella sativa in patient with hyperlipidemia.this study will be a single center study, utilizing a randomized, double-blind, placebo controlled trial. it will be conducted in the department of pharmacology, bsmmu in collaboration with the department of cardiology, bsmmu from the day of approval by the institutional review board to june, 2024. the study will involve a total of eighty four (84) patients attended in the outpatient department of cardiology, bsmmu, diagnosed as hyperlipidemia, with 42 of them receiving standard treatment along with a twice daily dose of 500mg of nigella sativa capsule for 8 weeks. the remaining 42 patients will undergo standard treatment along with a placebo over the same duration. the data collected will be analyzed through descriptive statistical techniques, offering a comprehensive summary of the results. in this study we will assess various sociodemographic characteristics of all the participants, including like age, sex, body mass index (bmi).in addition to these factors we will also evaluate their lipid profile, serum glutamic pyruvic transaminase (sgpt), serum creatinine level at baseline and after 8 weeks of interventions. addition of nigella sativa with the conventional treatment of statin could potentially reduce blood lipids in patients with hyperlipidemia.

Eligibility criteria:
inclusion criteria: 1. newly diagnosed hyperlipidaemic patient. 2. both male and female 3. hyperlipidemic patients suffering from ischemic heart disease, diabetes mellitus, hypertension 4. diagnostic criteria for dyslipidemic patients 1. total cholesterol 200mg/dl 2. ldl-c 140mg/dl 3. triglyceride 150mg/dl 4. hdl \<40mg/dl exclusion criteria: 1. patients with renal impairment 2. patients with active liver disease 3. patients having history of hypersensitivity on any member of statins 4. pregnant woman. 5. lactating mother
a growth artificial intelligence algorithm for length and weight study

Conditions: Length; Weight

Summary: this is a data collection and machine learning accuracy testing project that aims to a) collect training data to enhance, by machine learning, an artificial intelligence (ai) algorithm for measuring length in infants and young children and b) test the accuracy of the ai algorithm by comparing the ai predicted length with the gold standard measured length. images and videos will be collected by care givers and healthcare professionals, together with physical length measurements. these data will be used to train the ai algorithm and to explore potential improvements. other data to be collected is user experience feedback.


Eligibility criteria:
inclusion criteria: 1. infants/young children aged 0 to 24 months old at enrolment; 2. caregiver(s) have access to the internet and a smartphone or tablet to complete questionnaires, take images and videos, and upload these; 3. written informed consent from one or both caregivers (according to local laws) or legally acceptable representative(s) aged ≥ 18 years at enrolment. exclusion criteria: 1. children unable to undergo length or weight measurements when applying standardized techniques recommended by the who (e.g. infants/children with structural abnormalities of the lower limbs or orthopaedic conditions (e.g. club foot, hip dysplasia)). 2. research staff's uncertainty about the caregiver's ability or willingness to complete the study according to the instructions

Keywords: artificial intelligence length weight algorithm
a trial of a multi-component individualized telephone-based support intervention for adult-child caregivers caring for parents with dementia

Conditions: Dementia

Summary: this is the first randomized controlled trial exploring the implementation of a multi-component individualized telephone-based support intervention for adult-child caregivers caring for parents with dementia in china. results hold the potential to inform the further development of family caregiver supportive services.

the objectives of this study are to evaluate the efficacy and feasibility of a multi-component individualized telephone-based support intervention (heart) for adult-child caregivers caring for parents with dementia in china. the primary hypothesis to test is whether the heart is more efficacious in reducing caregiver burden than the follow-up as usual (fu) in dementia adult-child caregivers. secondary hypotheses include the following: 1. the heart is more efficacious in improving health related quality of life than the fu in dementia adult-child caregivers. 2. the heart is more efficacious in protecting reciprocal filial piety than the fu in dementia adult-child caregivers. 3. the heart is more efficacious in relieving cr's behavioral and psychological symptoms of dementia (bpsd) than the fu in dementia adult-child caregivers. 4. the heart group has a higher satisfaction with the intervention than the fu group. in addition, two research questions will be answered by qualitative data from process evaluation for the feasibility of the heart intervention. the research questions are as follows: 1. to what extent can the heart intervention be delivered as planned? 2. what are the barriers to and facilitators of the heart intervention?

Eligibility criteria:
inclusion criteria: * primary caregivers being adult children (age 18 or older) who have spent at least 2 hours per day over the last 3 months caring for a parent with a diagnosis of dementia. * must have telephone access. * caregivers will not end their primary caregiving role within 6 months of study enrollment. exclusion criteria: * cognitive impairment or intellectual disability. * those who are providing care for another relative with chronic physical or mental diseases. * pregnant women (because it is unlikely that this group would be primary caregivers except in exceptional circumstances, the consideration of which was beyond the scope of this research).
study to assess how abbv-951 is absorbed when administered at different subcutaneous sites of adult participants with parkinson's disease

Conditions: Parkinson's Disease

Summary: parkinson's disease (pd) is a neurological condition, which means it affects the brain. this study will evaluate how abbv-951 is absorbed under the skin of participants with pd when administered to arm, thigh and flank compared to the abdomen. abbv-951 is an investigational drug being developed for the treatment of pd. study doctors randomly assign participants to 1 of 4 groups, called treatment arms. each treatment arm receives abbv-951 administered in a different order in the arm, high, flank and abdomen. approximately 12 adult participants over 30 years with a diagnosis of pd will be enrolled in approximately 10 sites in the united states. participants will receive continuous (24hours/day) subcutaneous infusion of abbv-951 for 2 consecutive days for each infusion site (arm, thigh, flank and abdomen), for a total duration of treatment up to 12 days. there may be higher treatment burden for participants in this trial compared to their standard of care. participants will be confined at a hospital or clinic. the effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires. adverse events will be monitored throughout the study.


Eligibility criteria:
inclusion criteria: * diagnosis of idiopathic parkinson's disease (pd) that is levodopa-responsive. * must be taking a minimum of 400 mg/day of levodopa equivalents (le) and be judged by the investigator to have motor symptoms inadequately controlled by current therapy. * must have recognizable/identifiable "off" and "on" states (motor fluctuations), and have a minimum daily average of 2.5 hours of "off" time (with a minimum of 2 hours of "off" time each day). exclusion criteria: - history of significant skin conditions or disorders (e.g., psoriasis, atopic dermatitis, etc.) or evidence of recent sunburn, acne, scar tissue, tattoo, open wound, branding, or colorations that in the investigator's opinion would interfere with the infusion of the study drug or could interfere with study assessments.

Keywords: parkinson's disease foslevodopa/foscarbidopa abbv-951 levodopa (ld) carbidopa (cd)
impact of music therapy on intraoperative patient comfort during cataract surgery with topic anesthesia

Conditions: Cataract; Anxiety

Summary: cataract surgery with topic anesthesia is anxiety provoking. this operative stress can increase pain perception and blood pressure. this discomfort can lead to non-compliance with immobility and potentially lead to intraoperative and postoperative complications. pharmacological means are limited to reduce anxiety. only anxiolytics could be effective but at the cost of side effects not compatible with surgery. music care is a "digital treatment" allowing the diffusion of music with a u-shaped sequence using the principles of hypnoanalgesia. the objective of this study is to evaluate the effectiveness of the musiccare listening device on the anxiety of patients during cataract surgery with topic anesthesia


Eligibility criteria:
inclusion criteria: * cataract surgery with topical anesthesia exclusion criteria: * hearing impaired patient
early diagnosis of oxaliplatin-induced portal hypertension

Conditions: Gastroesophageal Varices; Colorectal Cancer; Received Oxaliplatin-based Chemotherapy

Summary: oxaliplatin has been used as the first choice for the adjuvant chemotherapy of colorectal cancer and it has significantly improved the outcomes in patients with colorectal cancer. however, hepatotoxicity is the potentially problematic adverse effect of oxaliplatin. the pathological evaluation of non-tumoral liver from patients with advanced colorectal cancer undergoing neoadjuvant oxaliplatin-based treatment has provided histological evidence of hepatic sinusoidal injury. oxaliplatin-induced sinusoidal injury can persist for more than 1 year after the completion of chemotherapy, and the increase in splenic volume may be a predictor of irreversible sinusoidal damage. in this current study, the investigators aim to evaluate the values of potential biomarkers in diagnosing patients with oxaliplatin-induced gastroesophageal varices after colorectal cancer surgery.


Eligibility criteria:
inclusion criteria: * male or female patients aged 18-75 * had a history of oxaliplatin-based chemotherapy for the treatment of colorectal cancer surgery; exclusion criteria: * combined known etiologies of chronic liver disease, including hepatitis, primary biliary cirrhosis, schistosomiasis, and non-alcoholic fatty liver disease. * with colorectal cancer required further anti-tumor treatment

Keywords: portal hypertension splenomegaly colorectal carcinoma oxaliplatin hepatotoxicity